The value of medical and biological stock market soared by 100 billion yuan, and the three stocks rose by more than 100%

[pharmaceutical network pharmaceutical stock market] in recent years, due to the impact of the epidemic, the pharmaceutical and biological sector has enjoyed a good momentum, with the outbreak of virus detection products, anti-virus and other related concept stocks Industry statistics show that since January 20, excluding the scientific and technological innovation board, the value of pharmaceutical and biological stock market has soared 154.4 billion yuan Among them, there are three stocks with an increase of more than 100%, namely Lianhuan pharmaceutical, Wuzhong, Jiangsu Province and Ogilvy medical Lianhuan pharmaceutical industry: up 134.39% and Lianhuan pharmaceutical industry up 134.39% Since the outbreak of the epidemic, the concept of antiviral stocks represented by Lianhuan pharmaceutical industry has increased dramatically As for the soaring share price, the company pointed out that it mainly produces urinary system drugs, antihistamines and cardiovascular drugs, and the sales revenue and proportion of antibiotics used to relieve cold symptoms and treat bacterial and fungal infections are very small The company did not sell other drugs that can be used for the treatment of respiratory system diseases Wuzhong, Jiangsu: up 125.48%; Wuzhong, Jiangsu: up 125.48% In the evening of February 7, Jiangsu Wuzhong announced that by the end of February 7, 2020, the company's dynamic P / E ratio was 104.14 times, with a high dynamic P / E ratio For media reports, market rumors and hot concepts, Jiangsu Wuzhong said in the announcement that the company's stock price has increased significantly in the near future, and the company once again reminded the risk that abidol hydrochloride is one of the products in production and sale of Jiangsu Wuzhong Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company From January to September 2019, the sales revenue of Wu Zhong medicine abidol hydrochloride tablets was 16.028 million yuan, accounting for 1.06% of the operating revenue of the listed company; the sales revenue of the same period in 2018 was 5.839 million yuan, accounting for 0.42% of the operating revenue of the listed company The sales revenue of the drug accounts for a very small proportion of the operating revenue of the listed company In addition, ribavirin injection is one of the products in production and sale of Wuzhong pharmaceutical, a wholly-owned subsidiary The data shows that from January to September 2019, the sales revenue of ribavirin injection of Wuzhong pharmaceutical was 2313900 yuan, accounting for 0.15% of the operating revenue of the listed company; the sales revenue of the same period in 2018 was 3686900 yuan, accounting for 0.26% of the operating revenue of the listed company The sales revenue of the drug accounts for a very small proportion of the operating revenue of the listed company Ogilvy medical: up 109.61%, Ogilvy medical's up more than 100%, to 109.61% The novel coronavirus pneumonia epidemic in Wuhan and other parts of the country has increased significantly, and demand for protective clothing such as respirators has increased significantly, according to the announcement recently Ogilvy medical products mainly include disposable medical consumables such as wound and dressing care, surgery / surgery, infection protection, combined package, etc Once again, the company solemnly reminds investors that protective equipment such as masks is only one of the company's many product categories, and the recent increase in the demand for protective equipment such as masks will not have a significant impact on the company's financial situation Can pharmaceutical and biological stocks still rise? At present, there is a large differentiation in pharmaceutical bio stocks Many stocks have a high correction after a continuous rise, and the number of stocks falling and stopping is more than 10 However, many securities companies are still optimistic about pharmaceutical bio stocks For example, CITIC Securities believes that the investment opportunities of follow-up pharmaceutical stocks are still worthy of attention In the medium term, medical demand will only be postponed, but the total amount will not be reduced, focusing on the marginal improvement of performance after the outbreak In the long run, the investment in medical and health costs will continue to increase, and the medical sector is worth re matching However, the industry also believes that, as the epidemic situation may show signs of improvement, it may have a negative impact on pharmaceutical stocks; in addition, some pharmaceutical stocks have been over hyped, and will return to performance in the future, and systematic opportunities have ended